pimobendan 5 mg tablet
Treatment of canine congestive heart failure
COMPOSITION
Each tablet contain pimobendan 5 mg
Indications
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation).
or the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease
Administration
Do not exceed the recommended dosage.
Determine the bodyweight accurately before treatment to ensure correct dosage.
The dose should be orally administered and within the dose range of 0.2 mg to 0.6 mg pimobendan/kg bodyweight, divided into two daily doses. The preferable daily dose is 0.5 mg/kg bodyweight, divided into two daily doses (0.25 mg/kg bodyweight each). Each dose should be given approximately 1 hour before feeding.
This corresponds to:
One 5 mg chewable tablet in the morning and one 5 mg chewable tablet in the evening for a body weight of 20 kg.
Chewable tablets can be halved at the score line provided, for dosage accuracy, according to the bodyweight.
The product may be combined with a diuretic, e.g. furosemide.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years
Shelf life after first opening the bottle: 100 days
Use any divided tablet at the next administration time.
Storage
Do not store above 25°C.
Keep the bottle tightly closed in order to protect from moisture.